1 to 10 of 44
Sort by

Library Entry
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer

Peritoneal carcinomatosis (PC) is a common and devastating manifestation of colon cancer and refractory to conventional anticancer therapeutics. During the peritoneal dissemination of colon cancer, peritoneal immunity is nullified by various mechanisms of immune evasion. Here, the authors...

Library Entry
Clinical landscape of oncolytic virus research in 2020

Oncolytic viruses (OVs) are a new class of cancer therapeutics. This review was undertaken to provide insight into the current landscape of OV clinical trials. The authors conclude that their data provides insight into the current profile of OV clinical trials reporting and identifies potential...

Library Entry
Initial dose of oncolytic myxoma virus programs durable antitumor immunity independent of in vivo viral replication

Oncolytic therapy uses live-replicating viruses to improve the immunological status of treated tumors. Critically, while these viruses are known to self-amplify in vivo, clinical oncolytic therapies still appear to display a strong dose dependence and the mechanisms mediating this dose...